So revenue went up 1000 % between 2015 and 2016?
Revenues and Cost of Sales
The Company had revenues of $83,500 and $209,573 for the three and nine months ended September 30,2016, respectively, compared to revenues of $1,755 and $20,212 for the three and nine months ended September 30,
2015, respectively. The Company generated revenues primarily from sales of its TetraStem antibiotic which presently is sold primarily through local physicians and the license fee. Cost of sales was ($5,984) and ($8,298) for the three and nine months ended September 30, 2016, respectively, compared to cost of sales of ($7,661) and ($9,886) for the three and nine months ended September 30, 2015, respectively. We expect sales to grow during the latter part of 2016 as we build awareness for our products and attempt to sell to larger pharmaceutical product retailers. We also
expect margins to improve if we are successful in selling larger volumes of our products.